Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback